The U.S. Supreme Court's recent ruling in a generics-labeling case, which offers a new shield against liability for safety warnings, has thrown a wrench into thousands of pending lawsuits and class actions involving copycat versions of some major drugs. Report
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments